This Article  • PDF of this Correction  • Original article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Women's Health  • Menopause  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2001;285:2858.

In the Original Contribution entitled "Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults: A Randomized Equivalence Trial" published in the March 7, 2001, issue of THE JOURNAL (2001;285:1155-1163), wording and level errors appeared. On page 1158, the last sentence in the first paragraph in column 3 should be: "In the as-treated analysis, the proportion of patients who had HIV RNA levels of 50 copies/mL or less was greater in the indinavir-lamivudine-zidovudine group for both strata: 76% (74/97) vs 88% (76/86) with a treatment difference of - 12% (95% CI, - 23% to - 1%) for the low baseline HIV RNA stratum and 57% (30/53) vs 74% (45/61) with a treatment difference of - 17% (95% CI, - 34% to 0%) for the high baseline HIV RNA stratum." On page 1162, the last sentence in the first full paragraph should be: "The difficulty in achieving an undetectable viral load among patients with high baseline HIV-1 RNA levels supports the need to initiate antiretroviral treatment in a manner consistent with treatment guidelines.^1,2"

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?